Becton Dickinson (MEX:BDX) Short Interest

View and export this data going back to 2018. Start your Free Trial

What is Becton Dickinson Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Becton Dickinson's Short Interest

For the Medical Instruments & Supplies subindustry, Becton Dickinson's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Becton Dickinson's Short Interest Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's Short Interest distribution charts can be found below:

* The bar in red indicates where Becton Dickinson's Short Interest falls into.

Becton Dickinson Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton Dickinson & Co (MEX:BDX) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

BDX:USA 1BDX:Italy 0R19:UK BOX:Germany BOX:Germany BOX:Germany BDX:Austria

Address

1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880

Website

https://www.bd.com

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.